Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Asia Pacific Consensus states that levofloxacin-based triple therapy as an alternative second-line therapy after Helicobacter pylori (H. pylori) eradication failure when bismuth salts are not available. The investigators compare the efficacies of 10-day levofloxacin-based sequential therapy and 10-day triple therapy in the treatment for patients after failure of standard triple therapy and to determine what clinical and bacterial factors influencing the efficacy of salvage regimens.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chang Gung Memorial Hospital
• Treatments: Amoxicillin; Esomeprazole; Levofloxacin; Metronidazole; Ofloxacin

Criteria

Inclusion Criteria:

• Consecutive H. pylori-infected participants, at least 18 years of age, with endoscopically proven peptic ulcer diseases or gastritis who failed first-line eradication therapies with standard triple regimens (PPI twice daily, 500 mg of clarithromycin twice daily and 1 g of amoxicillin twice daily)

Exclusion Criteria:

• Ingestion of antibiotics, bismuth, or proton-pump inhibitors within the prior 4 weeks

• Use of non-steroidal anti-inflammatory drugs within the prior 4 weeks

• Participants with allergic history to the medications used

• Participants with previous gastric surgery

• The coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)

• Pregnant women.